Login Register Cart 0
Generic placeholder image

Current Drug Therapy

Editor-in-Chief

ISSN (Print): 1574-8855
ISSN (Online): 2212-3903

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Novel Swellable/Expandable Gastroretentive Floating Films of Gliclazide Folded in Capsule Shell for the Effective Management of Diabetes Mellitus: Formulation Development, Optimization and In Vitro Evaluation

Author(s): Diksha Sharma and Deepak Sharma*

Volume 16, Issue 1, 2021

Published on: 01 December, 2020

Page: [100 - 112] Pages: 13

DOI: 10.2174/1574885515999201201122710

Price: $65

Abstract

Background: Gliclazide (GLZ) belongs to the second-generation of sulphonylureas; it is a drug of choice for the management of type II DM. It belongs to BCS Class II. The major site of drug absorption for GLZ is the stomach; it displays variation in the drug absorption rate and bioavailability due to the shorter gastric retention time. The floating mechanism gets affected when the gastric fluid level is not sufficiently higher, which ultimately obstructs the floating behavior, which is the major limitation of reported formulations. This limitation can be overcome by folding the film into the capsule shell dissolved in the gastric fluid and the film swells/expands to dimensions higher than pylorus sphincter (12mm), thus preventing its evacuation.

Objective: The study aims to explore the floating mechanism in the design of films along with a tendency to expand by swelling and unfolding by utilizing a mixture of hydrophilic and hydrophobic polymer to achieve the controlled drug delivery and prolonged gastric retention of drug.

Methods: The gastroretentive floating films were formulated by the solvent casting technique using 32 full factorial designs and subjected to in vitro evaluation parameters, drug-excipient compatibility, Xray diffraction and accelerated stability study.

Results: The pre-formulation study established the purity and identification of a drug. FTIR study confirmed no drug excipient interaction. F3, F6, and F9 were optimized based on in vitro floating characteristics, swelling/expanding ability, and unfolding time. All developed formulations were unfolded within 14-22 min after capsule disintegration. The F3 was selected as the final formulation as its ability to control the release of the drug for 24 hrs followed by zero-order kinetics having super case 2 transport. XRD confirmed the amorphousness of the drug within the formulation. The stability study results revealed that the formulation was quite stable at extreme storage conditions.

Conclusion: The developed novel formulation has good potential for the effective management and treatment of diabetes mellitus.

Keywords: Floating films, gliclazide, diabetes mellitus, gastric retention, floating time, bioavailability, controlled drug release.

« Previous Next »
Graphical Abstract

[1]
Kharroubi AT, Darwish HM. Diabetes mellitus: The epidemic of the century. World J Diabetes 2015; 6(6): 850-67.
[http://dx.doi.org/10.4239/wjd.v6.i6.850] [PMID: 26131326]
[2]
Deepthi B, Sowjanya K, Lidiya B, Bhargavi RS, Babu PS. A modern review of diabetes mellitus: an annihilatory metabolic disorder. J In Silico In Vitro Pharmacol 2017; 3(1): 1-5.
[3]
Olokoba AB, Obateru OA, Olokoba LB. Type 2 diabetes mellitus: a review of current trends. Oman Med J 2012; 27(4): 269-73.
[http://dx.doi.org/10.5001/omj.2012.68] [PMID: 23071876]
[4]
Chipirishetti R, Bondu AK, Adil MS, Challa RR. Comparative study of glimepiride and gliclazide in type 2 diabetes patients on safety, efficacy and tolerability. J Drug Deliv Ther 2015; 5(3): 10-2.
[http://dx.doi.org/10.22270/jddt.v5i3.1141]
[5]
Rojanasthien N, Autsavakitipong T, Kumsorn B, Manorot M, Teekachunhatean S. Bioequivalence study of modified-release gliclazide tablets in healthy volunteers. ISRN Pharm 2012; 2012375134
[http://dx.doi.org/10.5402/2012/375134] [PMID: 23029622]
[6]
Kamath H, Sivakumar A. Microemulsion based formulation as drug delivery system for gliclazide. Indian J Pharm Edu Res 2017; 51(4S): S571-9.
[http://dx.doi.org/10.5530/ijper.51.4s.85]
[7]
Nazief AM, Hassaan PS, Khalifa HM, Sokar MS, El-Kamel AH. Lipid-based gliclazide nanoparticles for treatment of diabetes: formulation, pharmacokinetics, pharmacodynamics and subacute toxicity study. Int J Nanomedicine 2020; 15: 1129-48.
[http://dx.doi.org/10.2147/IJN.S235290] [PMID: 32110012]
[8]
Awasthi R, Kulkarni GT. Decades of research in drug targeting to the upper gastrointestinal tract using gastroretention technologies: where do we stand? Drug Deliv 2016; 23(2): 378-94.
[http://dx.doi.org/10.3109/10717544.2014.936535] [PMID: 25026414]
[9]
Gupta R, Tripathi P, Bhardwaj P, Mahor A. Recent advances in gastro retentive drug delivery systems and its application on treatment of H. Pylori infections. J Anal Pharm Res 2018; 7(4): 404-10.
[http://dx.doi.org/10.15406/japlr.2018.07.00258]
[10]
Kumari B. Recent development in floating drug delivery system: a review. Asian J Pharm Pharmacol 2018; 4(2): 131-9.
[http://dx.doi.org/10.31024/ajpp.2018.4.2.6]
[11]
Bahri-Najafi R, Mostafavi A, Tavakoli N, Taymouri S, Shahraki MM. Preparation and in vitro-in vivo evaluation of acyclovir floating tablets. Res Pharm Sci 2017; 12(2): 128-36.
[http://dx.doi.org/10.4103/1735-5362.202451] [PMID: 28515765]
[12]
Vo AQ, Feng X, Morott JT, et al. A novel floating controlled release drug delivery system prepared by hot-melt extrusion. Eur J Pharm Biopharm 2016; 98: 108-21.
[http://dx.doi.org/10.1016/j.ejpb.2015.11.015] [PMID: 26643801]
[13]
Mandal UK, Chatterjee B, Senjoti FG. Gastro-retentive drug delivery systems and their in vivo success: a recent update. Asian J Pharm Sci 2016; 11: 575-84.
[http://dx.doi.org/10.1016/j.ajps.2016.04.007]
[14]
Rajput G, Majmudar F, Patel J. Formulation and evaluation of mucoadhesive glipizide films. Acta Pharm 2011; 61(2): 203-16.
[http://dx.doi.org/10.2478/v10007-011-0017-3] [PMID: 21684847]
[15]
Wagh PK, Ahirrao SP, Kshirsagar SJ. Gastroretentive drug delivery systems: a review on expandable System. Indian J Drugs 2018; 6(3): 142-51.
[16]
Schneider F, Koziolek M, Weitschies W. In vitro and in vivo test methods for the evaluation of gastroretentive dosage form. Pharm 2019; 11: 1-29.
[http://dx.doi.org/10.3390/pharmaceutics11080416]
[17]
Prakash S, Bhandari A, Mishra R, Sharma PK. Development and optimization of floating microspheres of gliclazide. Int J Pharm Sci Res 2015; 6(5): 806-17.
[18]
Jadhav VS, Chandratrey P. Formulation and evaluation of floating tablet of gliclazide using HPMC and xanthan gum. Int J Pharm Tech Res 2015; 7(1): 132-8.
[19]
Awasthi R, Kulkarni GT. Development of novel gastroretentive drug delivery system of gliclazide: hollow beads. Drug Dev Ind Pharm 2014; 40(3): 398-408.
[http://dx.doi.org/10.3109/03639045.2013.763817] [PMID: 23418961]
[20]
Manubolu K, Sujatha B, Sreenivasulu M, Kumar SR, Kumar SN, Rao KB. Formulation and in vitro evaluation of gliclazide microbeads. World J Pharm Res 2015; 4(5): 1970-82.
[21]
Sharad KK, Sunita SS. Design and development of fast dissolving tablet of gliclazide. J Dev Drugs 2017; 6(3): 177.
[http://dx.doi.org/10.4172/2329-6631.1000177]
[22]
Jadav S, Malothu N, Vancha H, Golla C, Ramaswamy NT. Formulatiom and evaluation of gastroretentive amlodipine besylate capsule. J Glob Trends Pharm Sci 2017; 8(2): 3805-12.
[23]
Shakya R, Thapa P, Saha RN. In vitro and in vivo evaluation of gastroretentive floating drug delivery system of ofloxacin. Asian J Pharm Sci 2013; 8: 191-8.
[http://dx.doi.org/10.1016/j.ajps.2013.07.025]
[24]
Jagdale SC, Patil S, Kuchekar BS. Application of design of experiment for floating drug delivery of tapentadol hydrochloride. Comput Math Methods Med 2013; 2013625729
[http://dx.doi.org/10.1155/2013/625729] [PMID: 23878616]
[25]
Fatema K, Mouzam MI, Shahi SR, Shaikh T. Formulation and evaluation of archimedes based novel floating capsule through film formation and retention for drug delivery of levofloxacin. Int J Pharm Sci Res 2017; 8(3): 1110-23.
[26]
Sivaneswari S, Karthikeyan E, Chandan PJ. Novel expandable gastro retentive system by unfolding mechanism of levetiracetam using simple lattice design - Formulation optimization and in vitro evaluation. Bull Fac Pharm Cairo Univ 2017; 55: 63-72.
[http://dx.doi.org/10.1016/j.bfopcu.2017.02.003]
[27]
Sharma N, Awasthi R. Development and characterization of novel gastroretentive raft forming floating film of atenolol. Indian Drugs 2015; 52(3): 15-23.
[28]
Bhardwaj P, Singh R, Swarup A. Development and characterization of newer floating film bearing 5-fluorouracil as a model drug. J Drug Deliv Sci Technol 2014; 24(5): 486-90.
[http://dx.doi.org/10.1016/S1773-2247(14)50092-5]
[29]
Rao MRP, Karanjkar PB. Formulation and development of gastroretentive drug delivery system of efavirenz. Int J Pharm Sci Drug Res 2019; 11(5): 231-40.
[http://dx.doi.org/10.25004/IJPSDR.2019.110513]
[30]
Karemore MN, Avari JG. Formulation, optimization, and in vivo evaluation of gastroretentive drug delivery system of nifedipine for the treatment of preeclampsia. AAPS PharmSciTech 2019; 20(5): 200.
[http://dx.doi.org/10.1208/s12249-019-1391-2] [PMID: 31127399]
[31]
Ullah MB, Karim MR, Alam MS, Hassan MR, Bhuiyan MA, Rana MS. Formulation and in vitro evaluation of unfolding type expandable gastroretentive film of enalapril maleate. Bangladesh Pharm J 2017; 20(2): 148-56.
[http://dx.doi.org/10.3329/bpj.v20i2.37868]
[32]
Shifana M, Sivakumar R, Harsha KJ, Haribabu Y. Formulation design and optimization of expandable gastro retensive film for controlled release of propranolol hydrochloride. Saudi J Med Pharm Sci 2018; 4(7): 835-41.
[33]
Meka VS, Dharmanlingam SR, Kolapalli VRM. Formulation of gastroretentive floating drug delivery system using hydrophilic polymers and its in vitro characterization. Braz J Pharm Sci 2014; 50(2): 431-9.
[http://dx.doi.org/10.1590/S1984-82502014000200023]
[34]
Rimawi IB, Muqedi RH, Kanaze FI. Development of gabapentin expandable gastroretentive controlled drug delivery system. Sci Rep 2019; 9(1): 11675.
[http://dx.doi.org/10.1038/s41598-019-48260-8] [PMID: 31406203]
[35]
Darandale SS, Vavia PR. Design of a gastroretentive mucoadhesive dosage form of furosemide for controlled release. Acta Pharm Sin B 2012; 2(5): 509-17.
[http://dx.doi.org/10.1016/j.apsb.2012.05.004]
[36]
Sathish D, Himabindu S, Kumar PP, Rao YM. Preparation and evaluation of novel expandable drug delivery system. Br J Pharm Res 2013; 3(4): 1079-93.
[http://dx.doi.org/10.9734/BJPR/2013/4891]
[37]
Davoudi ET, Noordin MI, Kadivar A, Kamalidehghan B, Farjam AS, Javar HA. Preparation and characterization of a gastric floating dosage form of capecitabine. BioMed Res Int 2013; 2013495319
[http://dx.doi.org/10.1155/2013/495319] [PMID: 24288681]
[38]
Prasad BR, Bhikshapathi DVRN. Design and in vivo evaluation of controlled release gliclazide trilayer matrix tablets in the management of diabetes mellitus. Int J Pharm Sci Drug Res 2018; 10(5): 410-7.
[39]
Hiremath SN, Raghavendra RK, Sunil F, et al. Dissolution enhancement of gliclazide by preparation of inclusion complexes with β-cyclodextrin. Asian J Pharm 2008; 2(1): 73-6.
[http://dx.doi.org/10.4103/0973-8398.41572]
[40]
Saha T. Preparation and evaluation of immediate release gliclazide tablet using super disintegrants. Int J Pharmacol 2018; 5(5): 294-7.
[41]
Muzib YI, Kumari KS. Mucoadhesive buccal films of glibenclamide: development and evaluation. Int J Pharm Investig 2011; 1(1): 42-7.
[http://dx.doi.org/10.4103/2230-973X.76728] [PMID: 23071919]
[42]
Karatas A, Baykara T. Studies on indomethacin inserts prepared by water-soluble polymers. II. The relation between dissolution rate and swelling behaviour. Farmaco 2001; 56(3): 197-202.
[http://dx.doi.org/10.1016/S0014-827X(01)01044-8] [PMID: 11409327]
[43]
Chen Y-C, Ho H-O, Liu D-Z, Siow W-S, Sheu M-T. Swelling/floating capability and drug release characterizations of gastroretentive drug delivery system based on a combination of hydroxyethyl cellulose and sodium carboxymethyl cellulose. PLoS One 2015; 10(1)e0116914
[http://dx.doi.org/10.1371/journal.pone.0116914] [PMID: 25617891]
[44]
Sharma D, Sharma A, Garg R. Design development and in vitro/ex vivo evaluation of mucoadhesive buccal film of benzydamine hydrochloride for the effective treatment of aphthous stomatitis Recent Pat Drug Deliv Formul 2018; 12(4): 277-94.
[http://dx.doi.org/10.2174/1872211313666190128151038] [PMID: 30706830]

Rights & Permissions Print Cite
Article Metrics
21
1
© 2024 Bentham Science Publishers | Privacy Policy